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PURPOSE. The International Myopia Institute (IMI) Yearly Digest highlights new research
considered to be of importance since the publication of the first series of IMI white
papers.
METHODS. A literature search was conducted for articles on myopia between 2019 and
mid-2020 to inform definitions and classifications, experimental models, genetics, inter-
ventions, clinical trials, and clinical management. Conference abstracts from key meetings
in the same period were also considered.
RESULTS. One thousand articles on myopia have been published between 2019 and mid-
2020. Key advances include the use of the definition of premyopia in studies currently
under way to test interventions in myopia, new definitions in the field of pathologic
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myopia, the role of new pharmacologic treatments in experimental models such as
intraocular pressure–lowering latanoprost, a large meta-analysis of refractive error iden-
tifying 336 new genetic loci, new clinical interventions such as the defocus incorpo-
rated multisegment spectacles and combination therapy with low-dose atropine and
orthokeratology (OK), normative standards in refractive error, the ethical dilemma of
a placebo control group when myopia control treatments are established, reporting the
physical metric of myopia reduction versus a percentage reduction, comparison of the
risk of pediatric OK wear with risk of vision impairment in myopia, the justification
of preventing myopic and axial length increase versus quality of life, and future vision
loss.
CONCLUSIONS. Large amounts of research in myopia have been published since the IMI
2019 white papers were released. The yearly digest serves to highlight the latest research
and advances in myopia.
Keywords: myopia, classification, definitions, high myopia, pathologic myopia, genet-
ics, emmetropization, interventions, atropine, contact lenses, spectacles, orthokeratology,
management guidelines, clinical trials, axial length, cycloplegia
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The International Myopia Institute (IMI) consensus groupwas founded in 2015 by the late Professor Brien Holden
(BHVI, Sydney) following the joint World Health Organiza-
tion (WHO) and BHVI Meeting on Myopia held in Sydney.
The IMI was formed to facilitate the sharing of evidence-
based findings related to the worldwide significant increase
of myopia with practitioners, researchers, and policy makers.
The initial impetus for the IMI was to develop consen-
sus definitions of myopia, high myopia, and pathologic
myopia, as well as recommendations on treatment strategies
to prevent myopia onset and to slow myopia progression,
especially in low-income settings, and to promote basic and
clinical research on myopia.1
The subsequent International Myopia Conference Meet-
ing (IMC) in 2015 further highlighted the need for a consen-
sus group and led to the collaboration between the IMC and
IMI, which resulted in the formation of the initial seven task
forces that produced the first series of IMI white papers on
myopia. Wolffsohn et al.1 details the history of the IMI. This
was a truly global collaborative effort, and today the IMI has
over 130 experts involved in 13 taskforces. The first white
papers were published in Investigative Ophthalmology and
Visual Science (IOVS) in 2019, a process chaired by Profes-
sors Earl Smith, James Wolffsohn, and Serge Resnikoff and
facilitated by Dr. Monica Jong.
Professor Serge Resnikoff accepted the role of chair of
IMI in 2018, and since the publication of the first IMI white
papers, IMI has pursued its mission to disseminate evidence-
based information to advance research, education, and
myopia management to prevent future myopia-related vision
loss and blindness. Recent key achievements include the IMI
definitions2 being referenced at the ICD-11 Revision Techni-
cal meeting in 2019, the IMI white papers being referenced
in the WHO World Report on Vision, clinical summaries
derived from the IMI white papers being translated into
12 languages, dedicated sessions being included at key
practitioner and scientific meetings, and five new 2021 IMI
white papers published in this special issue of IOVS. Rais-
ing awareness for myopia and high myopia as a signif-
icant public health issue is an ongoing process involv-
ing the collective efforts of researchers, clinicians, industry,
policy makers, and various groups that work with children.
More voices calling for collective action are necessary to
move this area forward and ensure the latest evidence-based
practice.
A search of PubMed using the term “myopia” from 2019
to mid-2020 alone yielded almost 1000 peer-reviewed
articles. In other words, almost 1000 articles have been
published since the first series of IMI white papers (2019).
This presents a daunting challenge in trying to keep
up with the latest information. The yearly digest is a
simple and convenient way for clinicians and researchers
to access the recent highlights in myopia. The yearly
digests are organized around six of the original seven
IMI white papers. The taskforce members producing the
digests were involved in the original IMI white papers
and have curated between 3 and 10 of the most poten-
tially impactful articles published in their area from 2019
to the mid-2020, with personal insights. Various online
databases were searched from 2019 up to mid-2020, and
notable conference presentations that featured myopia
such as the IMC 2019, Tokyo Medical and Dental Univer-
sity, and the ARVO 2020 virtual meeting were included.
The Yearly Digest updates readers in the key advances in
myopia in the following sections until the next series of
these IMI white papers are published:
• Defining and classifying myopia
• Experimental models of emmetropization and
myopia
• Genetics of myopia
• Interventions for controlling myopia onset and
progression
• Clinical myopia control trials and instrumentation
• Clinical management guidelines for myopia
IMI DIGEST 2021—DEFINING AND CLASSIFYING
MYOPIA
The IMI “Defining and Classifying Myopia” white paper
proposed definitions for myopia, high myopia, and patho-
logic myopia based on statistical analysis of thresholds used
in the literature and clinical relevance (Table 1 and Table 2).2
Previously, over 400 definitions had been used in the liter-
ature, and many different cutoffs for myopia and high
myopia had been suggested. This caused some confusion
for differentiating various grades of myopia, in particular for
the delineation of high myopia and pathologic myopia.2,3
Standardizing definitions will ease evidence-based manage-
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Myopia A refractive error in which rays of light entering the eye parallel to the optic axis are brought to a
focus in front of the retina when ocular accommodation is relaxed. This usually results from the
eyeball being too long from front to back but can be caused by an overly curved cornea or a lens
with increased optical power, or both. It is also called near sightedness.
Axial myopia A myopic refractive state primarily resulting from a greater than normal axial length.
Refractive myopia A myopic refractive state that can be attributed to changes in the structure or location of the image
forming structures of the eye (i.e., the cornea and lens).
Secondary myopia A myopic refractive state for which a single, specific cause (e.g., drug, corneal disease, or systemic
clinical syndrome) can be identified that is not a recognized population risk factor for myopia
development.
Quantitative definitions
Myopia A condition in which the spherical equivalent refractive error of an eye is ≤ –0.50 D when ocular
accommodation is relaxed.
Low myopia A condition in which the spherical equivalent refractive error of an eye is ≤ –0.50 D and > –6.00 D
when ocular accommodation is relaxed.
High myopia A condition in which the spherical equivalent refractive error of an eye is ≤ –6.00 D when ocular
accommodation is relaxed.
Premyopia A refractive state of an eye of ≤ +0.75 D and > –0.50 D in children where a combination of baseline
refraction, age, and other quantifiable risk factors provide a sufficient likelihood of the future
development of myopia to merit preventative interventions.
TABLE 2. Definitions for the Structural Complications of Myopia2,29
Term Definition
Descriptive definitions
Pathologic myopia Excessive axial elongation associated with myopia that leads to structural changes in the posterior
segment of the eye (including posterior staphyloma, myopic maculopathy, and high
myopia-associated optic neuropathy) and that can lead to loss of best-corrected visual acuity.
Myopic macular degeneration
(MMD)
A vision-threatening condition occurring in people with myopia, usually high myopia that comprises
diffuse or patchy macular atrophy with or without lacquer cracks, macular Bruch´s membrane
defects, choroidal neovascularization, and Fuchs spot.
Diagnostic subdivisions of MMD
Myopic maculopathy Category 0: no myopic retinal degenerative lesion.
Category 1: tessellated fundus.
Category 2: diffuse chorioretinal atrophy.
Category 3: patchy chorioretinal atrophy.
Category 4: macular atrophy.
“Plus” features: lacquer cracks, myopic choroidal neovascularization, and Fuchs spot.
Presumed myopic macular
degeneration
A person who has vision impairment and vision acuity that is not improved by pinhole, which
cannot be attributed to other causes, and
The direct ophthalmoscopy records a supplementary lens > –5.00 D and shows changes such as
“patchy atrophy” in the retina or
The direct ophthalmoscopy records a supplementary lens > –10.00 D.
Specific clinical conditions characteristic of pathologic myopia
Myopic traction maculopathy
(MTM)
A combination of macular retinoschisis, lamellar macula hole, and/or foveal RD (FRD) in highly
myopic eyes attributable to traction forces arising from adherent vitreous cortex, epiretinal
membrane, internal limiting membrane, retinal vessels, and posterior staphyloma.
Myopia-associated glaucoma-like
optic neuropathy
Optic neuropathy characterized by a loss of neuroretinal rim and enlargement of the optic cup,
occurring in highly myopic eyes with a secondary macrodisc or parapapillary delta zone at a
normal intraocular pressure.
ment of myopia and improve comparability of research
outcomes. Since the publication of the IMI white paper on
the myopia definitions, several studies have been published
and selected here for commentary. These studies further
highlight the need for standardization of the myopia defi-
nitions and show that definitions may be selected based
on the relevant population and what is being evaluated as
an outcome. In addition to defining thresholds for myopia
and pathologic myopia as a structural and not a refrac-
tive concept, a range of other terms were defined such
as premyopia, secondary myopia, myopic traction macu-
lopathy (MTM), and myopia-associated glaucoma-like optic
neuropathy (MAGON) (further discussed in the IMI 2021
white paper: “IMI Pathologic Myopia”4). These terms are
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starting to become more widely used and are further
discussed below.
Myopia Thresholds
In relation to the standardization of refractive thresholds,
several articles have explicitly cited the proposed stan-
dards.5,6 The need for standardization of definitions is high-
lighted by the continued publication of papers with vary-
ing definitions for high myopia.7 For example, a recent
refractive surgery study defined a threshold for high myopia
at –9.00 D.8 This paper, like many others, also high-
lighted the issue of the inconsistent use of the mathe-
matical symbols for “less than” in relation to myopia, in
that extremely high myopia was described as ≥ –9.00 D,
but the context indicates that this was intended to mean
more myopic than –9 D, rather than a refractive error ≥ –
9.00 D. Another recent paper defined high myopia as “as
the presence of a highly negative refractive error (>−6.00
to −8.00 D),” again using the mathematical symbol “>”
to mean “more myopic” when mathematically, it should
be written as “<” to indicate a more negative value and
more myopia.9 The IMI definitions and classifications white
paper2 proposed that mathematical symbols should be
used in a strict mathematical sense for consistency and
that words be used where potential ambiguity arises (e.g.,
“more than 6.00 D of myopia” or “more myopic2 than
–6.00 D”).
Achieving complete consistency in reporting refractive
errors is unlikely to be achieved in the short term. One
suggestion in the IMI white paper2 for reporting standards
for myopia studies was that when different thresholds are
used to better suit the research question, a sensitivity anal-
ysis should be performed at the chosen and standardized
thresholds (i.e., spherical equivalent refraction ≤ –0.5 for
myopia and ≤ –6.0 D for high myopia). This would be invalu-
able when it comes to comparing studies or performing
meta-analyses. The value of this approach has been demon-
strated in a paper published prior to the IMI report10 and
supported in a paper published in 2020.11 The cutoff values
for myopia have a strong effect on the estimated prevalence
of myopia and high myopia in population-based studies. For
example, in the study by Parssinen and Kauppinen,12 defin-
ing high myopia as a spherical equivalent refraction < –6.00
D in the right eye or by a spherical equivalent of ≤ –6.00
D or ≤ –5.00 D in either eye was associated with a myopia
prevalence of 24%, 32% and 52%, respectively.
The recent publication of normative standards for refrac-
tive errors is also a step forward. San-Diez et al.13 reported
axial length growth curves for Chinese children for esti-
mating the risk of myopia, based on age, gender, the axial
length/corneal radius ratio, and spherical refractive error.
The growth curves were based on a data set from 12,554 chil-
dren aged 5 to 16 years from Wuhan, China. Compared with
the axial length growth curves for European children of the
same age,13b the Chinese children had significantly longer
axial lengths. San-Diez and colleagues13 used a threshold of
−5.00 D, but this study was initiated prior to the publication
of the IMI white paper.2 The definition of centile-based stan-
dards to refraction offers a rational basis for an age-adjusted
definition of high myopia in children and adolescents, in
whom the development of high myopia in adulthood is likely
or very likely. Refraction reference curves in European chil-
dren have also been published but were noncycloplegic.14
More longitudinal studies will be needed to validate these
approaches.
In the IMI definitions white paper,2 the proposed defi-
nition of myopia did not stipulate cycloplegia as a require-
ment but included the caveat “when ocular accommodation
is relaxed” (Table 1). This was intentional to avoid potentially
invalidating many epidemiologic studies in adults. Cyclople-
gia remains the gold standard in studies of refractive error in
children,15 but in some settings, for example, school screen-
ings, cycloplegia can be impractical, but the data are still
useful (covered in detail in the “IMI Clinical Myopia Control
Trials and Instrumentation” white paper).16 From a func-
tional point of view, the various degrees of myopia may be
defined by the uncorrected visual acuity of the respective
refractive error. Introducing unaided distance visual acuity
criteria could be useful to avoid overdiagnosing myopia due
to instrument myopia when cycloplegia is not used.17
Other Definitions: Premyopia and Secondary
Myopia
The concept of premyopia has emerged over the past
few years, and the IMI proposed a practical definition
of this concept (Table 1). Several clinical trials, notably
the ATOM3 study from Singapore (NCT03140358, https:
//clinicaltrials.gov/ct2/show/NCT03140358), are currently
recruiting premyopes to test whether atropine can delay
or prevent myopia onset. Premyopia is now also being
discussed in the context of a comprehensive approach to
myopia progression management.18 Secondary myopia is a
potentially useful concept but remains rarely used in this
field, despite being a widely adopted term in other condi-
tions (e.g., glaucoma). It has appeared recently in several
publications as an exclusion criterion19,20 and in a review
on the perennial “nature versus nurture” question.21
Pathologic Myopia
In relation to terminology and definitions, the area that
remains in greatest flux is the concept of pathologic myopic.
New classifications are still being proposed, and it is likely to
be some time until a clear consensus emerges in this area.9
Rather than a refractive definition, the concept of patho-
logic myopia was defined in purely structural terms as a set
of complications that arise from high myopia with increas-
ing age.2 The understanding of structural complications and
their visual implications continues to evolve.22 Several recent
papers provide excellent data on the risk of such complica-
tions and the impact on vision.23,24 Although high myopia–
related ocular complications are recognized to increase with
age, particularly after age 50 years, these complications are
now also being recognized in highly myopic children.25
The continual refinement of optical coherence tomography
(OCT) will undoubtedly contribute to improving the under-
standing of pathologic myopia, and one specific OCT-based
definition—myopic traction maculopathy (MTM), which is
becoming more widely used. The clinical characteristics of
MTM are becoming well defined,26 and a staging system
has now been proposed.27 The impact of high myopia
on optic nerve structure and function, as encapsulated in
the term myopia associated glaucomatous optic neuropathy
(MAGON) is also a topic of current research and interest.28
For a detailed discussion, please refer to the IMI 2021 white
paper “IMI Pathologic Myopia.”4
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Conclusion
Standardization of myopia thresholds and definitions is
improving, but much work remains to be done on this topic.
Meta-analyses are now a very important aspect of myopia
research, and use of consistent standards will enhance the
potential of this powerful statistical approach. The field of
pathologic myopia is rapidly evolving, and new classifica-
tions are likely to emerge over the coming years, led by both
growing clinical interest in the topic and advances in imag-
ing technology.
IMI DIGEST 2021—EXPERIMENTAL MODELS OF
EMMETROPIZATION AND MYOPIA
The discovery of the phenomenon of form-deprivation
myopia in 1977 ushered in the modern era of animal
research on refractive development.30 The 2019 IMI white
paper on experimental models of emmetropization and
myopia31 reviewed the significant progress that was
achieved via research involving laboratory animals over the
following 40+ years. Since then and through 2020, research
involving animal models has continued to expand and to
provide new and critical insights into factors that influ-
ence ocular growth and refractive development and that
contribute to the genesis of common refractive errors like
myopia. This digest highlights some of the high-interest,
high-impact papers that have been published during the
intervening period. The highlighted papers were selected
based on a survey of the authors of the 2019 IMI experimen-
tal models paper.32 The accompanying reference list includes
papers that were published since submission of the experi-
mental models paper, specifically 3 more recent reviews,32–34
3 papers that involved nonhuman primates,35–37 3 that
employed tree shrews,38–40 14 that used chickens,41–54 19
that involved guinea pigs55–72 and 22 that utilized mice.73–94
While the chicken continues to be a mainstay in experi-
mental myopia research, the number of publications using
guinea pigs and mice has increased, particularly in the latter,
to take advantage of the genetic manipulations that are
possible in the mouse.
Intraocular Pressure and Myopia Progression
El-Nimri NW, Wildsoet CF. Effects of topical latanoprost
on intraocular pressure and myopia progression in young
guinea pigs. Invest Ophthalmol Vis Sci. 2018;59:2644–2651.66
Intraocular pressure (IOP) has been hypothesized to be a
contributing factor to myopia progression, primarily because
the biomechanically weaker scleras in myopic eyes would be
more susceptible to the stretching influence of IOP. If this
were true, treatment strategies that lower IOP should slow
axial myopic progression. In this respect, clinical trials using
the β-blocker, timolol, the only ocular hypotensive drug to
be clinically tested, have yielded inconsistent results. Simi-
larly, timolol failed to reduce the degree of form-deprivation
myopia in chickens, possibly because β-blockers have mini-
mal effects on IOP at night when myopic growth appears to
dominate.
El-Nimri and Wildsoet66 demonstrated that topical
latanoprost, a prostaglandin analogue, was effective in
reducing IOP over 24 hours in guinea pigs, and more
importantly, this commonly used ocular hypotensive drug
was effective in blocking the axial myopia produced by
form deprivation. In addition, they observed that latanoprost
normalized the diurnal IOP rhythms in deprived eyes and
that the observed reductions in myopic axial elongation
were correlated with the magnitude of the IOP reductions,
supporting a biomechanical explanation for the myopia
control effects. This investigation is in agreement with
a recent study by Liu et al.,95 who showed that the α-
adrenoreceptor agonist, brimonidine, which is a different
class of ocular hypotensive from latanoprost, was also effec-
tive in reducing IOP and defocus-induced myopia in guinea
pigs.
At present, alternative IOP-independent explanations for
the actions of these drugs cannot be ruled out. Further inves-
tigations into underlying site and mechanisms of action for
the myopia control effects for both latanoprost and brimoni-
dine are needed. Nevertheless, the results of these studies
are exciting because they indicate that well-tolerated, topi-
cally administered, ocular hypotensive drugs may provide a
qualitatively new line of myopia control therapy.
The Role of ON and OFF Channels in Refractive
Development
Wang M, Aleman A, Schaeffel F. Probing the potency of arti-
ficial dynamic ON or OFF stimuli to inhibit myopia develop-
ment. Invest Ophthalmol Vis Sci. 2019;60:2599–2611.54
The ON and OFF channels originate at the sign-inverting
and sign-conserving synapses between the photoreceptors
and the ON and OFF bipolar cells, respectively. These chan-
nels remain largely separate through the retina, the lateral
geniculate nucleus, and the early stages of cortical process-
ing. Evidence associated with genetic mutations, pharma-
ceutical interventions, and manipulations of the temporal
luminance profiles of ambient lighting indicates that selec-
tive interruptions/adaptations of the ON and OFF retinal
channels can have qualitatively different effects on normal
emmetropization and vision-induced alterations in refractive
development.
In this paper, the most recent in a series of papers
on this topic from the Schaeffel lab, the authors investi-
gated the effects of dynamic ON or OFF visual stimuli on
choroidal thickness (CT), a predictive indicator of the direc-
tion of refractive development. In addition, they investi-
gated the associated changes in retinal dopamine release,
a key element in the signal cascade that regulates ocular
growth that is dependent on ON-pathway activity. The
primary findings were that in both humans and chickens, ON
stimuli produced choroidal thickening, whereas OFF stim-
uli caused choroidal thinning. In chickens, ON stimulation
also elevated dopamine release when compared to OFF stim-
ulation. An unexpected finding in chickens was that over
longer treatment periods, both ON and OFF stimulation were
associated with increased myopia in response to imposed
hyperopic defocus, even though relative to OFF stimulation,
ON stimulation increased dopamine, a known inhibitor of
myopia.
This study is noteworthy because the results show that
dynamic ON and OFF local luminance stimuli have qualita-
tively similar effects on CT in humans and chickens. The fact
that dopamine release also varied in a bidirectional manner
supports the hypothesis that dopamine is involved in the CT
changes produced by ON and OFF stimuli. Significantly, the
direction of changes in CT produced by these dynamic lumi-
nance stimuli agreed with previous findings from the Scha-
effel lab obtained in participants viewing texts of different
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contrast polarities. It will be important to determine the time
course for the effects of these dynamic ON and OFF stimuli
because it may be possible to manipulate signals in the ON
or OFF pathways in ways that are not dependent on retinal
focus but that can selectively alter axial elongation rates and
the progression of myopia.
Circadian Clocks and Refractive Development
Stone, RA, McGlinn AM, Chakraborty R, et al. Altered ocular
parameters from circadian clock gene disruptions. PLoS One.
2019;14(6):e0217111.87
Many ocular processes show diurnal oscillations that
are relevant to ocular growth and refractive development.
In growing eyes, axial length and choroidal thickness
exhibit circadian rhythms that are altered by visual condi-
tions that are known to interfere with normal refrac-
tive development. In animals with experimentally induced
myopia, diurnal rhythms in retinal dopamine turnover
and the expression of circadian rhythm–related genes are
altered. The fact that manipulations of the intensity and
diurnal cycle of ambient lighting, key factors in coordi-
nating diurnal rhythms, also alter refractive development
suggests that ocular circadian rhythms play a role in
emmetropization and the development of common refractive
errors.
In this intriguing paper, the authors investigated the
effects of disrupting clock genes on optical development
in 2 very phylogenetically different species, the mouse and
the fly (Drosophila melanogaster). In comparison to litter-
mate control mice (Bmal1fl/fl), retinal specific knockouts for
Bmal1, an essential component of the circadian clock, exhib-
ited myopic refractive errors that, like common myopia in
children, were associated with increases in vitreous cham-
ber depth. In Drosophila, knockouts of either the cycle or
period genes in the circadian clock resulted in an elonga-
tion of the fluid-filled pseudocones of the ommatidia, an
optical component considered analogous to the vitreous
chamber in the camera eyes of vertebrates. Thus, it appears
that circadian clocks influence the pathways that regu-
late ocular development in both of these widely separated
species.
It is known that the basic molecular mechanisms for circa-
dian rhythms are conserved from Drosophila to mammals.
This study demonstrates that at least some aspects of these
mechanisms that play a role in regulating optical develop-
ment have also been conserved across species and that the
maintenance of normal ocular diurnal rhythms is fundamen-
tal to normal emmetropization. This study provides further
evidence that genetic and environmental factors that influ-
ence diurnal rhythms can produce alterations in optical
development of the eye that are similar in nature to those
associated with common refractive errors like myopia. These
findings support the idea that it may be possible to manipu-
late ambient lighting and societal behaviors that potentially
impact circadian rhythms in ways that reduce the burden of
myopia.
Contribution of Cone Pathway Signaling in
Form-Deprivation Myopia
Chakraborty R, Yang V, Park HN, et al. Lack of cone mediated
retinal function increases susceptibility to form-deprivation
myopia in mice. Exp Eye Res. 2019;180:226–230.73
Elegant experiments in animal models using partial
diffusers have demonstrated that refractive eye growth
depends on detection of visual input by the retina.96,97
However, the retinal signaling pathways that control refrac-
tive development and myopic eye growth remain elusive.
Rod and cone photoreceptor pathways are fundamental to
light detection across a large range of luminance. While
there is experimental evidence that both rods and cones
contribute to normal refractive development,98,99 cones have
been thought to be more influential due to their roles in high
acuity and color vision.
Chakraborty et al.73 set out to investigate the role of
cone photoreceptor signaling in normal refractive develop-
ment and form deprivation myopia by using a mouse model
with a gene mutation in Gnat2, the α-subunit of cone trans-
ducin. The Gnat2–/– mice have loss of cone function with
normal rod function. The authors found that the loss of cone
function did not influence normal refractive development
in mice. However, the Gnat2–/– mice were more suscepti-
ble to form deprivation myopia, showing a ∼65% increase
in myopic shift compared to wild-type control mice after
3 weeks of goggling.
These results suggest that the retinal signaling for normal
emmetropization and the response to form deprivation may
not be the same. Cones were not essential for normal refrac-
tive development but significantly influenced the suscepti-
bility to form deprivation. Interestingly, these authors have
previously reported on the response of a mouse with
loss of rod function, Gnat1–/–, which showed opposite
effects.98b The absence of rod signaling results in a “flat”
refractive development curve and unresponsiveness to form-
deprivation myopia. Thus, rods and cones appear to play
different roles in refractive eye growth: cones may modu-
late the response to form deprivation, while rods may be
required to respond to form deprivation.
Importantly, these experiments take advantage of the
mouse model of myopia in which genetic and environmen-
tal factors can be altered. The ability to genetically modify
specific ocular cell types or pathways of interest is unique to
the mouse model and provides an opportunity to examine
how a given mutation alters normal refractive development
across age as well as the response to myogenic stimuli. Such
an approach is expected to offer new insights into the mech-
anisms controlling refractive eye growth and eventually to
lead to new treatment targets.
Genes, Environment, and Interactions Drive
Refractive Development
Tkatchenko TV, Shah RL, Nagasaki T, Tkatchenko AV. Anal-
ysis of genetic networks regulating refractive eye develop-
ment in collaborative cross progenitor strain mice reveals
new genes and pathways underlying human myopia. BMC
Med Genomics. 2019;12:113.91
The increase in the prevalence of myopia is attributed
to both environmental and genetic factors as well as the
interplay between them. While the global rise of myopia is
happening too rapidly to be solely caused by genetic factors,
it is well documented that genetics play a role in the risk
of developing hyperopia and myopia. As Dr. Judith Stern
famously said, “Genetics loads the gun but the environment
pulls the trigger,”99b succinctly illustrating the idea that the
interactions between genes and the environment are respon-
sible for driving the progression of many complex diseases,
such as hyperopia and myopia.
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FIGURE 1. Historic overview of myopia gene finding from 1990 to 2020. Genes identified using whole exome sequencing (WES) are marked
in purple. Other loci (linkage studies, GWAS) are marked in red. The cohorts used in the GWAS studies are indicated in black.
In this novel experiment, Tkatchenko et al.91 evaluated
how genetic backgrounds of different mouse strains inter-
act with the visual environment to affect refractive error. By
tracking the refractive errors of 8 genetically different mouse
strains, they uncovered differences in refractive develop-
ment between strains placed in normal and myopigenic envi-
ronments. To further understand why some mouse strains
are more susceptible to myopia than others, Tkatchenko
et al.91 performed RNA sequencing on the retinas from these
strains to evaluate differential gene expression. In doing
so, they identified thousands of genes and multiple path-
ways responsible for normal refractive development in mice,
many of which overlap with findings in human studies.
Intriguingly, they found that while many genes were associ-
ated with both normal refractive development and myopia
susceptibility, they tended to act in opposite directions.
The integration of both phenotypic measures and tran-
scriptomic data in this study provides a powerful approach
to understanding the molecular underpinnings of refractive
error development. Additionally, these findings are likely
relevant for human myopia, as many of the identified biolog-
ical pathways and genes are conserved across species. Over-
all, this study identified well-defined retinal signaling path-
ways that may be responsible for driving ocular growth
in response to the visual environment, which could guide
approaches in drug development and treatment (also see
the recent review by Tkatchenko and Tkatchenko33).
IMI DIGEST 2021—GENETICS OF MYOPIA
Introduction
Myopia is a complex disorder in which both genetic influ-
ences and environmental factors play a role. Since the first
genome-wide association study (GWAS) in 2010, the number
of loci associated with refractive error has increased dramat-
ically due to larger samples sizes. Recently, over 500 loci
have been associated with refractive error (Fig. 1). The genes
residing within these loci are involved in a variety of path-
ways, including light-processing pathways, retinal cell phys-
iology, glutamate receptor signaling, circadian rhythm regu-
lation, dopamine pathway, and extracellular matrix organiza-
tion. Expression analyses of identified genes have implicated
a role for almost all ocular cell types in the pathogenesis
of myopia. While more and more loci have been associated
with myopia, the exact mechanisms by which they confer
susceptibility to this trait are still largely unknown. Further-
more, most of the heritability of refractive error (defined
as the proportion of interindividual variation in the trait
contributed by genetics) remains unexplained. Some of the
missing heritability might be explained by gene–gene and
gene–environment interaction, but a significant fraction of
causally related genes for refractive error has yet to be
discovered. There have been some key updates to the field of
myopia genetics since the publication of the IMI white paper
on myopia genetics.100 The PubMed database was searched
using various MeSH terms (e.g., “myopia/genetics,” "refrac-
tive errors/genetics,” "genetic predisposition to disease") to
identify articles published between February 2019 and April
2020. Most of these articles focused on gene-discovery in
(pathologic) myopia101–104 the genetic overlap with myopia-
related complications,105,106,126 epigenetics,78,85,107,108 tran-
scriptomics,109–113 proteomics113,114,120 and the interaction
between environmental factors and genetics.115,116 The key
advances are highlighted below in Figure 2.
Commentary
Gene Finding. Perhaps the most important break-
through in the past 12 months was the publication by Hysi
et al.101 of the largest GWAS meta-analysis of refractive
error to date, which included over 500,000 participants of
European ancestry. This study combined data from the UK
Biobank, the consumer genomics company 23andMe Inc.,
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FIGURE 2. Overview of myopia genetics research.
and the Genetic Epidemiology Research on Adult Health and
Aging study for discovery, along with data from the CREAM
consortium for replication. The authors also carried out a
meta-analysis including all studies; this meta-analysis iden-
tified 449 loci, of which 336 represented new genetic loci.
This work confirmed that refractive error is genetically an
extremely heterogeneous disorder involving many different
processes, genes, and ocular tissues. Among the newly iden-
tified genes are genes regulating circadian rhythm, genes
with known roles in corneal dystrophies, cataract and reti-
nal dystrophies, genes in the Wnt signaling pathway, and
genes with prominent effects on skin, hair, and eye pigmen-
tation. Two major sets of mechanisms were proposed by the
authors: first, those affecting ocular structure, development,
and physiology, including IOP, and second, central nervous
system–related genes, such as those with effects on retinal
signaling pathways.
In addition to gene discovery, the authors assessed
whether the newly identified genetic loci could be used to
detect individuals at risk of developing high myopia who
could possibly benefit from intervention (e.g., at-risk indi-
viduals could be targeted for early intervention with atropine
eye drops or dual-focus lenses designed to slow myopia
progression).117 A polygenic risk score (PRS) for refrac-
tive error had an area under the receiver operating char-
acteristics curve (AUC) of 0.75 for predicting high myopia
(defined as spherical equivalent [SER] < –5.00 D), which
compares favorably with previous methods for predicting
myopia based on cycloplegic refraction in young children.118
Another genetic study similarly derived a PRS for refractive
error that attained an AUC of 0.75 for predicting high myopia
and found that children with a PRS in the top 10% were at
6-fold higher risk of high myopia than those in the remain-
ing 90%.119 This latter study was based on a much smaller
sample than Hysi et al.,111 suggesting that there is hope for
even greater accuracy in genetic prediction of myopia in the
future. The genetic loci associated with myopia have rela-
tively small effect sizes, so identifying more loci will not
necessarily improve prediction of common myopia. Never-
theless, discovering even greater numbers of genes associ-
ated with refractive error development by enlarging GWAS
sample sizes and improving imputation quality and usage of
alternative genetic techniques will help to further elucidate
the pathogenesis of myopia.
Family Studies. One alternative technique to identify
genes, and highly penetrant rare variants in particular, is to
use family-based linkage studies, since any one particular
causal rare variant is more likely to be observed in multi-
ple affected individuals within a highly aggregated family
than to be observed in a sample of unrelated affected indi-
viduals. Linkage analysis takes advantage of long haplo-
types shared by related affected individuals and has good
power to detect high-penetrance variants in large pedigrees
with multiple affected individuals. Two new studies have
used this approach in families from 2 founder populations
in the United States, the Pennsylvania Amish102 and an
orthodox Ashkenazi Jewish community.103 In both studies,
pedigrees with a strong family history of common myopia
were enrolled, and exome-based microarray genotyping was
performed. Participants underwent extensive eye examina-
tions; myopia was defined as a mean spherical equivalent
≤ –1 D. An autosomal dominant model with a rare disease
allele was assumed in the 2-point parametric linkage analy-
ses. In the Amish families, genome-wide significant linkages
to myopia were identified at 12q15 and 8q21.3 across all
Amish families, centered on the genes PTPRB and CNGB3.
PTPRB (a protein tyrosine phosphatase) has not been previ-
ously linked to eye disease, although other protein tyro-
sine phosphatases have been implicated in myopia. CNGB3
is expressed in cones, and a genetic defect in this gene
underlies achromatopsia. Further, 3 genome-wide signifi-
cant linked variants were also found within a single Amish
family. These variants were all located in the gene SLC618,
which would be novel for eye disease. In the Ashkenazi fami-
lies, genome-wide significant linkage signals, not previously
associated with eye disease, were observed on 7q36.1 and
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8q24, centered on the genes SSPO and WISP1. This data set
also replicated a previously published linkage on 1p36.1.
Since linkage peaks are broad, the genes with the strongest
evidence for linkage above may not be causal. Genome-wide
sequencing of the most informative families in these data
will help identify the causal genes and variants.
Epigenetics. Individuals who develop myopia early in
life have a higher likelihood of progressing to high myopia.
This may be caused by myopia genes with expression and
effect early in life. Another explanation of this effect might
be related to epigenetic changes due to influences in utero.
Furthermore, epigenetic changes might influence myopia
development in childhood or even between generations.
Only a few studies have focused on epigenetic changes—
those possibly influenced by early environmental factors—in
myopia development.
An epigenome-wide association study by Seow et al.85
aimed to find CpG methylation sites in umbilical cord
tissue associated with early onset myopia. A study popu-
lation of 519 Malay, Indian, and Chinese children with
available umbilical cord blood and SER at 3 years was
included for analysis (29 cases [SER < –0.50 D] and 490
nonmyopic controls). Epigenetic signals were evaluated
at 160,418 separate loci after adjusting for ethnicity, sex,
gestational age, cellular composition, and batch effects.
Five CpG probes (cg21880079, cg14066632, cg03155767,
cg17154092, cg26299044) showed evidence of association
with myopia; all were hypomethylated in myopia cases
compared to controls (2.81% to 4.49% methylation change in
cases compared to controls). Adjusting for parental myopia
and smoking did not materially change the results. One of
the 5 sites was located in a known myopia locus (MYP10)
and 4 of the probes could be annotated to genes (ARL1,
FGB, PQLC1, KRT12). ARL1, PQLC1, and KRT12 showed
expression in both fetal and adult human ocular tissue,
whereas the FGB gene showed significant scleral expression
in ocular mouse tissue. The authors considered that all 4
genes might be involved in corneal epithelium development
and membrane transport. Umbilical cord blood was used to
investigate the methylation profile. Therefore, these results
may help in predicting early onset myopia but may not
fully reflect biological changes in ocular tissue. The authors,
however, suggest that the biological changes seen in early
onset myopia in very young children are already reflected
in umbilical cord tissue at birth. In addition, differentially
methylated CpG sites may be used as biomarkers to predict
high myopia in children. Replication in a larger data set and
examination of the correlation between umbilical cord tissue
methylation and eye tissue are warranted to strengthen the
evidence.
A second epigenetic study by Williams et al.107 exam-
ined DNA methylation at approximately 450,000 CpG sites
across the genome of 921 children of European ancestry
from the United Kingdom (ALSPAC study), using cord blood
samples collected at birth and peripheral blood samples
collected at age 7 and 15 years. The capacity of these
450,000 epigenetic probes to predict myopia at age 7 and
15 years was assessed using 10-fold cross-validation. The
AUC for predicting myopia at age 7 years was significantly
better than at age 15 years (P = 0.001), with an AUC
in the range of 0.60 to 0.64. Detailed analysis of 9 pres-
elected genes (APLP2, RASGRF1, GJD2, ZMAT4, LAMA2,
RBFOX1, TSPAN10, DRD1, CASC15) previously implicated
as being imprinted or involved in gene–environment interac-
tions were tested for enriched CpG sites whose methylation
level was associated with myopia at age 7 or 15 years. This
revealed an association of myopia at age 7 years with DNA
methylation at CpG site cg13403566 near RASGRF1 (uncor-
rected P = 6.4 × 10−5; Bonferroni-corrected P = 0.025). The
authors demonstrate stronger links of early epigenetic marks
with myopia at age 7 years rather than age 15 years in the
context of an intriguing observation that the prevalence of
myopia at age 7 years (but not 15 years) was lower if the
paternal grandmother had smoked in pregnancy. This asso-
ciation was primarily found among grandsons compared to
granddaughters. Smoking is one of the best-known environ-
mental exposures affecting epigenetic profiles, and several
examples of adverse or adaptive “transgenerational” inheri-
tance carried by epigenetic marks have been documented in
humans and animal models.107
Vishweswaraiah et al.108 studied epigenetic differences
in 18 children aged 4 to 12 years with a high degree of
myopia (SER ≤ –6 D) and 18 healthy controls from 1 Polish
center. The authors identified 1541 CpG sites in 1745 unique
genes with a 2-fold or higher differential methylation in the
high-myopia cases compared to controls. Methylation was
assessed using the EPIC array (with some 850,000 CpG)
probes from peripheral blood. The study of more extreme
cases may be a powerful approach, but on the other hand,
the small sample size means that firm conclusions cannot
be made and replication in much larger samples is needed.
Epigenetic mechanisms can also be explored using animal
models, which enable use of the relevant tissues.
Liang et al.78 successfully used this strategy; their study
was based on the hypothesis that HOXA9 plays a role in
myopia development similarly to other established home-
obox genes associated with myopia (PAX6 and MEIS1).
Moreover, HOXA9 is known to transcriptionally activate the
well-known myopia-associated transforming growth factor β
(TGF-β) signaling cascade. In the Growing Up in Singapore
Towards Healthy Outcomes birth cohort study, 8 preschool
children represented refractive error outliers (SER < –2 D),
and 7 of them had hypomethylation at HOXA9, suggesting
that overexpression ofHOXA9 could be a risk factor for early
onset myopia. The researchers then performed animal stud-
ies, measuringHOXA9 RNA levels in the retina of form depri-
vation myopia (FDM) mice (n= 9) by real-time polymerase
chain reaction (PCR). These levels in the retina of myopic
eyes were significantly higher (P= 0.029, paired t-test) than
of the uncovered fellow eye. Lastly, the cellular studies based
on murine retinal pigment epithelium (RPE) cells demon-
strated that an increase of HOXA9 could increase expres-
sion in several myopia-associated genes, including TGF-
β, FGF2, IGF1R, and MMP2. The authors concluded that
since HOXA9 is a transcription factor, it may directly or indi-
rectly affect expression of myopia-associated genes. Albeit
an elegant approach, there remains the need for replication,
a larger sample size, analyses on human eye–related tissue,
and bulk testing of multiple genes.
Transcriptomics (MicroRNAs). Regulatory mecha-
nisms have been implicated in myopiagenesis.121 While there
are many regulatory elements, such as enhancer RNAs, long
noncoding RNAs, and microRNAs (miRNAs), most studies
focused on miRNAs for their potential therapeutic role or as
a clinical biomarker. Several studies have performed miRNA
next-generation sequencing and quantitative PCR (qPCR)
on human aqueous humor derived at onset of cataract
surgery or refractive surgery between highly myopic versus
nonmyopic eyes. Zhu et al. detected differential expres-
sion between 249 mature miRNAs and 17 novel miRNAs in
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myopic eyes (age range 19–67 years) compared to control
eyes (age range 55–89 years). The authors postulated that
the TNF, MAPK, PI3K-Akt, and HIF-1 signaling pathways
might be regulated by these miRNAs. A subset of miRNAs
was confirmed by qPCR (hsa(homo sapiens)-let-7i-5p, hsa-
miR-127-3p, and hsa-miR-98-5p).109 Chen et al.110 focused
on exosomal miRNA profiles in aqueous humor and their
role in myopia development (n = 16 patients; 8 myopia (age
range 57–71 years) and 8 control (age range 57–87 years).
These exosomal miRNAs are likely involved in the pathogen-
esis of various eye diseases. The researchers found that the
numbers and sizes of exosomes were not significantly differ-
ent between the myopia and control group. The individual
exosomes of the same group were pooled to purify RNA.
Unexpectedly, the myopia group contained 2.78-fold more
RNA than that in the control group: 15 miRNAs were myopia
specific, and 4 miRNAs were absent in the myopia group.
Six well-known myopia-associated genes (CHRM2, CNGB3,
VEGFA, ADORA2A, IGF1 and LUM) were identified as poten-
tial targets for 5 myopia-specific miRNAs (hsa-miR-582-3p,
hsa-miR-17-5p, hsa-miR-885-3p, hsa-miR-19b-3p, and hsa-
miR-450b-5p).
Two reports on the novel topic of miRNA expression
in low-dose atropine treatment (0.003%) against myopia
development were published.111,112 Both studies focused
on gaining more insight into the molecular mechanism of
atropine on myopia treatment and defending the safety
of low-dose atropine treatment, using either human scle-
ral fibroblasts112 or human corneal epithelial cells.111 Hsiao
et al.112 identified slight changes in scleral gene expression
after 0.003% atropine treatment, supporting the safety of
low-dose atropine treatment. This study revealed the asso-
ciation of hsa-miR-2682-5p-KCNJ5 and hsa-miR-2682-5p-
PRLR with scleral growth repression and circadian rhythm.
Chang et al.111 analyzed the messenger RNA (mRNA) and
miRNA expression profiles between atropine-treated and
control corneal epithelial cells. They found that low-dose
(0.003%) atropine was associated with dysregulation of
certain genes. Several bioinformatics tools predicted that
this dysregulation might suppress the apoptosis of the
corneal epithelial cells, potentially through Ras and protein
kinase A signaling pathways. Hsa-miR-651-3p-EPHA7, hsa-
miR-3148-TMEM108, and hsa-miR-874-5p-TBX6 were vali-
dated as possible miRNA regulators of mRNA dysregulation
(i.e., miRNA–mRNA interaction) involved in corneal epithe-
lial cells treated with 0.003%. Although the findings of these
studies give more insight into the molecular mechanisms of
atropine treatment, the results should be replicated using
larger studies and similar human eye–related tissues. More-
over, studies should include the entire range of doses in
atropine treatment, since there is a clear dose–effect rela-
tionship between atropine and axial elongation.122,123
Proteomics. One important question is how differ-
ences in genetic background, miRNA expression, and methy-
lation translate to changes in protein expression and how
this relates to the development of myopia and pathologic
myopia. Currently, most studies focusing on proteomics
followed a candidate gene approach using vitreous humor.
Wei et al.113 investigated differences in protein expression
in vitreous humor of pathologic myopia (myopes with reti-
nal detachment [RD], macular hole, epiretinal membrane, or
retinoschisis) compared to healthy eyes (SER >−6.00 D and
axial length < 26.5 mm without any chorioretinal degenera-
tion) and discovered differences in levels of 2 antioxidative
proteins (PGDS, GPX3). Ding et al.120 used vitreous humor
of patients with vitreomacular interface disease as a control
group and discovered differences in expression of CTGF and
HGF in these patients compared to high-myopia patients.
A candidate gene study from Peng et al.114 found elevated
levels of DKK1, involved in the canonical Wnt/β-catenin
pathway, in the vitreous humor of pathologic myopia eyes.
These proteins could be potential drug targets for myopia
prevention treatments.
Animal Models. Previous work has demonstrated an
overlap between myopia susceptibility in humans and
animal models42,104 Regarding myopia pathways across
species and identification of major pathways, Tkatchenko
et al.91 examined normal refractive error development
and susceptibility to form-deprivation myopia using RNA
sequencing in 8 distinct mouse strains. An extensive review
of this publication can be found in this IMI 2021 yearly
digest section on experimental models. In short, the gene
sets controlling baseline refractive development and those
regulating susceptibility to myopia overlapped, but these
2 processes appeared to be controlled by largely distinct
sets of genes. The authors suggest that regulation of
emmetropization may be different from pathways that
modulate environmental influences, such as optical defo-
cus, and only a subset of the genes controls both processes.
An alternative explanation, derived from a chick study,
suggests that genes controlling normal variation in eye size
are distinct from genes conferring susceptibility to form-
deprivation myopia.125 Furthermore, Tkatchenko et al.91
performed a genome-wide gene-based association analy-
sis in the CREAM consortium and UK Biobank human
cohorts to identify mouse genes and pathways associated
with myopia in humans. They identified that 985 differen-
tially expressed mouse genes were associated with myopia
in humans, of which 847 were newly reported associations
and need validation in humans. However, the authors did
not clarify if such a large number of genes could have
been found simply by chance. Nevertheless, investigating
the consistency of findings from animal studies and human
genetic studies is a promising approach for elucidating the
causal mechanisms of the trait.
Shared Genetic Background Between Myopia
and Other Eye Diseases. Myopia is well known to
be associated with various complications such as RD, or
primary open angle glaucoma (POAG). It was unsurpris-
ing that several genetic loci associated with refractive error
overlapped with significant RD risk loci.105 A more interest-
ing aspect was the nature of those loci: BMP3 and ZC3H11B
were among the replicated RD risk loci, suggesting that
myopia-related pathways, such as eye elongation control,
may be more pertinent to RD risk than others. The authors
also remarked that PRSS56, which strongly associated with
high myopia, did not appear to impact RD. Together with
GWAS for other myopia-associated conditions and traits, RD
GWAS will help to better understand myopia heterogene-
ity and associated loci function. Risk of detachment seemed
to increase steadily with increasing polygenic myopia risk
score (PRS) population quintile—a risk score the authors
derived from a small fraction (n = 71) of significant vari-
ants from the previous CREAM refractive error GWAS121—
both for clinically ascertained rhegmatogenous RD and for
a less well-defined set of retinal detachments from the UK
Biobank.
The study by Han et al.106 examined the RD–myopia
link in a formal Mendelian randomization (MR) framework,
which can provide evidence for causality. MR studies can
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be thought of as “natural RCTs,” with the randomization
coming from the random assortment of alleles at conception.
The MR design can help avoid problems such as confound-
ing and provide genetic support for a causal link. By using
genetic data from the UK Biobank, Han et al.106 showed that
there is likely to be a causal link between myopia and RD,
with each 6-D decrease in refractive error leading to a 7.2-
fold increase in RD risk. By leveraging our understanding of
myopia genetics, knowledge about RD pathogenesis is also
increased, enabling the possible identification of potential
targets for prevention of RD in general and RD in myopes.
The clinical association between myopia and POAG
has been studied extensively. However, it was unclear
whether these 2 complex conditions share a common
genetic background. Iglesias et al.126 aimed to quantify
the degree of genetic overlap between myopia and POAG
(and POAG endophenotypes) in an Australian/New Zealand
(the Australian & New Zealand Registry of Advanced Glau-
coma study) and Dutch population-based cohort (the Rotter-
dam Study). PRSs were derived and the genetic correlation
between myopia and POAG, IOP, vertical cup to disc ratio,
cup area, disc area, and retinal nerve fiber layer was assessed
using a technique known as linkage disequilibrium score
regression analysis. Surprisingly, genetic predisposition to
myopia did not predict POAG status in either population.
In fact, evidence of a shared genetic architecture was only
found between myopia and optic disk area, which is in line
with previously found associations between refractive error
and optic disk size.124,127,128 Nevertheless, concluding that
there is no clear genetic association between myopia and
POAG, the authors were careful to point out that the rela-
tively small sample size and the challenge of diagnosing
POAG in myopic eyes were limiting factors. Interestingly, MR
in the largest GWAS to date, described above, showed that
higher IOP causes more negative spherical equivalent (more
myopia) in the general population, and this might explain
the previously suggested relationship between myopia and
glaucoma.101
Breaking Developments
The results from the largest GWAS meta-analysis to date for
refractive error confirmed that this approach continues to
yield new discoveries as sample sizes increase.101 As well
as providing opportunities to better understand the mecha-
nisms regulating myopia development via the discovery of
novel genes and pathways, these studies also offer potential
new targets for treatment of myopia and myopia progres-
sion.
The widespread availability of omics data enables new
discoveries in the field of myopia genetics.78,85,107–114,120
As discussed, 3 human epigenetic myopia studies were
published in the past year.85,107,108 Epigenetics might allow
greater understanding of how the environment causes
myopia but may require prospective longitudinal studies to
investigate changes of methylation signatures during life.
In healthy volunteers, we are usually limited to data from
blood. Epigenetic signals can be tissue specific; therefore,
studies should ideally be performed on samples of retina,
choroid, and sclera. Tissue samples taken during surgery for
other conditions may be a possible source. However, in the
absence of such samples, the studies above demonstrate a
role for surrogate tissues in the identification of biomarkers.
Finally, another significant development was the joint
analysis of data from animal models and human stud-
ies,91 which highlights the possibility of strengthening the
evidence and gaining new insights on novel pathways by
combining these data. In addition to finding new myopia
loci, future research should focus on understanding the
molecular signaling cascade leading to myopia. Defining
particularly the crucial steps in myopia pathogenesis will
help in discovering new potential molecules for targeted
intervention.
Conclusions
With increasing sample size of studies and new genetic
analysis techniques such as whole-genome sequencing and
gene–environment interaction analysis, we will find more
genetic loci in the future to explain the missing heritability
for refractive error. Genetic vulnerability to myopic compli-
cations such as myopic macular degeneration or RD as well
as genetic susceptibility to a positive response to treatment
should be the focus of future research as these have imme-
diate clinical impact. Furthermore, examining prenatal and
intergenerational influences on myopia development, such
as in the previously described epigenetic studies, is a first
step to explain how the environment has an impact at an
early stage in life. Methylation analysis and RNA sequenc-
ing data are valuable approaches, but the limited availability
of ocular tissue restricts widespread use in humans at this
moment.
For now, the great challenge of our field is to unravel the
pathophysiologic pathways from the current known genetic
loci. Next steps should be aimed at understanding how these
myopia genes contribute to certain biological processes,
how they interact together, and how they are influenced
by environmental factors, such as lifestyle. Subsequently,
when more insight is gained in the function of these genes,
they may be a starting point for new treatment options and
prevention strategies.
IMI DIGEST 2021—INTERVENTIONS FOR
CONTROLLING MYOPIA ONSET AND PROGRESSION
In a survey conducted in 2018 to 2019, eye care practition-
ers in many countries were found to be concerned about
the problem of myopia, yet most were not actively inter-
vening to slow myopia. Unfortunately, while 80% of prac-
titioners agreed that single-vision (SV) spectacles or under-
correction was not effective in slowing myopia, some 4 years
later, approximately 64% continued to prescribe SV refrac-
tive corrections, citing increased cost and inadequate infor-
mation as the reasons.130 Nonetheless, the search for myopia
control treatment has continued since the intervention white
paper in 2019,131 with studies over the intervening period
largely focused on understanding and improving the efficacy
of treatments. In this update, we summarize recent advances
for myopia control in relation to specially designed spectacle
and contact lens devices; topical atropine, which remains the
only pharmacologic treatment option; and some novel inter-
vention strategies. This update is largely limited to already
completed clinical trials.
Specially Designed Multiple Segment Focal
Spectacles
There is just 1 new study to report. In a 3-year
prospective, randomized, multicenter clinical trial, 600
myopic schoolchildren (age: 6 to 12 years, myopia: –1.00
to –4.00 D) were randomized to wear either a novel multifo-
Downloaded from iovs.arvojournals.org on 10/11/2021
IMI 2021 Yearly Digest IOVS | Special Issue | Vol. 62 | No. 5 | Article 7 | 12
cal lens design (defocus-incorporated multisegment [DIMS])
or SV lenses.132 The DIMS lens has a central distance optical
zone, with an annular peripheral zone incorporating multi-
ple small segments of positive power (∼ 1.03 mm in diame-
ter, +3.50 D), with the goal of imposing myopic defocus on
local peripheral retinal regions. At the end of the first 2 years
of this trial, myopia progression in the DIMS lens-wearing
group was significantly reduced relative to that of the SV
lens group; myopia increased by −0.38 ± 0.06 vs. −0.85 ±
0.08 D (expressed as spherical equivalent refraction [SER]),
and axial lengths increased by 0.21±0.02 vs. 0.56 ± 0.02
mm, respectively. These results represent improved efficacy
over previously tested multifocal spectacle lens designs. This
multisegment spectacle lens design is currently also being
trialed in northern China, although no results are yet avail-
able.133
Specially Designed Multifocal Contact Lenses
Three recent trials not only confirmed that it is feasible to
slow myopia with optical interventions, but like the specially
designed multisegment spectacle lens study, these trials also
reported substantially greater slowing of myopia than in
most previous trials.132,134,135
One of these trials, a 3-year, multicenter, double-masked,
randomized clinical trial, involved the MiSight 1 day
(ScottsVille, NY) contact lens, which was compared with SV
contact lens. Both lenses were prescribed on a daily wear,
daily disposable basis.134 Participants comprised 144 chil-
dren, aged between 8 and 12 years, with low to moder-
ate myopia (–0.75 to –4.00 D). Over the 3-year trial period,
myopia progressed by −0.51 ± 0.64 vs. −1.24 ± 0.61 D
(expressed as SER) and axial lengths increased by 0.30 ±
0.27 D vs. 0.62 ± 0.30 mm, representing a greater than 50%
reduction in progression with MiSight by both indices.
The second randomized clinical trial involved 508 chil-
dren, assigned to wear 1 of 4 test contact lenses; 2 were
based on an extended depth of focus principle, and 2 were
novel multifocal designs that imposed myopic defocus on
both central and peripheral retinal regions. SV daily dispos-
able lenses were included as the control reference.135 As in
the case of the MiSight lens trial, both changes in refrac-
tive errors and axial lengths over 2 years were significantly
lower in the groups wearing test lenses, ranging from −0.78
to −0.87 D (SER) and 0.41 to 0.46 mm compared to −1.15 D
(95% confidence interval [CI], –0.99 to –1.30) and 0.60 mm
(95% CI, 0.53 to 0.66 mm) in the SV lens group. Interestingly,
the rates of progression across the 4 test contact lenses were
not significantly different, and improved efficacy was also
linked to better wearer compliance in the case of the test
lenses.
The third trial was a 3-year, double-masked clinical trial
of 294 children with myopia randomized to wear soft center-
distance multifocal lenses with either a medium or high
add (+1.50 vs. +2.50 D) or an SV soft contact lens.136 The
choice of multifocal contact lens design aimed to provide
clear central vision while simultaneously focusing some
light in front of the retina to slow eye growth. The 3-year
adjusted myopia progression (SER) was –1.05 D with the
SV contact lenses compared to –0.60 and –0.89 D with the
high and medium add multifocal lenses, respectively. The
slowed myopia progression apparent in the refractive error
data is mirrored in the smaller axial length increases in the
high and medium add groups over the same period, of 0.42
and 0.58 mm, respectively, compared to 0.66 mm for the SV
group. Nonetheless, differences in progression between the
multifocal and SV lens groups reached statistical significance
only for the high add group. Also, unlike other reports,135
longer wearing times were not found to enhance the treat-
ment effect.
Orthokeratology
Research seeking to both understand the mechanism under-
lying the myopia control effect of orthokeratology (OK) and
improve its effectiveness is also ongoing. In one such retro-
spective longitudinal study of 103 subjects,137 both total
higher-order aberration root mean square and spherical
aberrations were found to be significantly and positively
correlated with axial length and negatively correlated with
axial elongation. Further studies are warranted to follow up
on the possibility that spherical aberration plays a key role
in the OK myopia control effect, as suggested by these data.
Although not specifically addressing the issue of myopia
control efficacy in relation to OK, one other OK study worthy
of mention monitored 66 children (6 to < 16 years) wear-
ing SV spectacles for 7 months before switching them to OK
for another 7 months.138 All children displaying rapid axial
elongation were found to benefit from OK, with younger
children (< 9 years), who tended to show more rapid axial
elongation compared to older children, benefiting most. On
the basis of these results, the authors suggested monitor-
ing progression for a period of time (3–6 months) before
intervening with OK, to ensure that the benefits from the
intervention outweighed the risks of serious adverse events,
given that OK is also a costly, time-consuming intervention
option.
Topical Atropine
In relation to topical atropine for myopia control, important
new findings since the 2019 white paper relate to (1) concen-
trations and (2) combination therapies. Late 2019 saw the
publication of results of phase 2 of the Low-Concentration
Atropine for Myopia Progression (LAMP) study.139 Phase
1 involved daily treatment of children (4 to 12 years, at
least 1.00 D myopia) with 0.01%, 0.025%, or 0.05% atropine,
with a placebo treatment also included. In phase 2, 383
of the 438 participants in phase 1 continued their origi-
nally assigned treatments, with the exception of the placebo
group, which was switched to 0.05% atropine. Over the
2-year trial period, increases in myopia for the 0.05%,
0.025%, and 0.01% concentrations were 0.55 ± 0.86 D, 0.85
± 0.73 D, and 1.12 ± 0.85 D, respectively, and increases in
axial lengths, 0.39 ± 0.35 mm, 0.50 ± 0.33 mm, and 0.59 ±
0.38 mm, respectively. Myopia progression (based on both
indices) in the placebo group decreased with the switch to
0.05% atropine for the second year of the trial. For both
the 0.05% and 0.025% concentrations, treatment effects were
comparable across both years. The overall treatment effect
with the 0.01% concentration lagged behind the 0.025% and
0.05% concentrations, which were also both well tolerated.
Note that both this study and the well-known ATOM series
of clinical trials involved East Asian sites. As atropine is
known to bind avidly to melanin, with pigmented ocular
tissues serving as a local reservoir, it will be of interest to
compare these published data with results from other ongo-
ing clinical trials of low-concentration atropine, such as The
Childhood Atropine for Myopia Progression in the UK study
(CHAMP)147b and the Myopia Outcome Study of Atropine in
Children (MOSAIC).148 Both of these trials involve multiple
sites distributed throughout United States and Europe, with
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much higher representations of Caucasian children, who
typically have less heavily pigmented ocular tissues than East
Asian children.
Results from a retrospective study and early findings from
a clinical trial combining topical 0.01% atropine with OK
lenses were also published in 2019. The underlying premise
of combination therapies is that overall treatment efficacy
can be improved, assuming that complementary rather than
shared mechanisms underlie each of the treatment effects.
In one retrospective study,140 60 children undergoing OK
were found to benefit from the addition of nightly 0.01%
atropine in the second year; axial elongation dropped from
0.46 ± 0.16 mm in the first year to 0.14 ± 0.14 mm, irre-
spective of age and refractive error, although those showing
the fastest progression in year 1 appeared to benefit most.
However, it should be noted that those who refused atropine
treatment were not included in the analysis as controls;
instead, the authors used a group of historical controls (n =
29) whose axial elongation was significantly different from
their test group (0.35 ± 0.11 mm) after 1 year of OK lens
wear (P = 0.0013). Nonetheless, these results are consis-
tent with results from an earlier, smaller-scale study141 and a
closely related 2-year clinical trial involving 59 myopic chil-
dren (6 to 11 years, –1.00 to –4.00 D).142 In the latter study,
the children were fitted with OK lenses, 29 of whom also
used 1 drop of 0.01% atropine nightly prior to insertion of
their lenses. Significantly less axial elongation was recorded
in those using the combination therapy (0.07 ± 0.16 vs.
0.16 ± 0.15 mm; P = 0.03) at the end of 12 months. Lens
performance was also reported to be unaffected with 0.01%
atropine use in this study. Recommendations on the value of
combining topical atropine with therapies involving multi-
focal manipulations must await further data, although the
apparent enhancement of the effect of imposed myopic defo-
cus on the peripheral retinal induced component of multifo-
cal ERG recording by topical 0.1% atropine is intriguing.143
Environmental Influences and Novel Treatments
While spending more time outdoors has been shown to
have therapeutic benefit, as reported in the early interven-
tion white paper, the mechanism underlying this protec-
tive effect remains to be resolved. While there are no new
studies to report here, the ongoing interest in novel treat-
ments for myopia and on refractive error development more
generally can be assessed indirectly through filed patents
(NCT03538002 and NCT03623074; clinicaltrials.gov); also,
there are ongoing trials related to environmental and opti-
cal interventions, although no published clinical data are
currently available.
IMI DIGEST 2021—CLINICAL MYOPIA CONTROL
TRIALS AND INSTRUMENTATION
The 2019 IMI—Clinical Myopia Control Trials and Instru-
mentation report reviewed the prospective evidence base
from existing myopia control trials of at least 1 year in
duration along with the supporting academic literature. The
review yielded recommendations on the design of future
clinical trials for determining the effectiveness of treatments
at slowing myopia progression and the impact of these
treatments on patients. Since the publication of the first
series of the IMI white papers to the end of 2019, 2 papers
have been published on spectacle interventions,133,144 3 on
soft contact lens trials (1 being an extension of an existing
cohort),134,135,145 1 orthokeratology study,146 4 on the effect
of administering atropine,147–150 and 2 trials of combined
atropine and soft contact lenses150 or OK.151
Participant Inclusion
These trials have all used cycloplegic refraction with partic-
ipant selection criteria of a maximum astigmatism from –
0.75 D to –2.50 D (generally higher for atropine studies),
maximum anisometropia of 1.00 to 1.50 D (although not
reported in several studies), minimum distance visual acuity
from 20/20 to 20/25, a minimum age from 6 to 8 years
(although 1 study included participants as low as 4 years of
age), and a maximum age typically between 11 and 13 years
(although 2 studies recruited children up to 15–16 years of
age) (Table 3). Recruiting patients with high astigmatism
could lead to them having a very different optical envi-
ronment (such as an increased depth of focus),152 making
it more difficult to evaluate the myopia intervention. The
progression of childhood myopia slows with age, so includ-
ing 15- to 16-year-old children in a trial that lasts several
years will reduce the apparent effectiveness of the interven-
tion when considering the actual reduction in eye growth
in millimeters or increase in myopia measured in diopters.
TABLE 3. Selection Criteria in Recent Myopia Control Clinical Trials




Limit (D) VA Min
Age, Min
to Max, y
Kanda et al., 2018144 Spectacle (novel plus design) –4.50 to –1.50 Y 1.50 1.50 20/20 6 to 12
Lam et al., 2020132 Spectacle (novel plus design) –5.00 to –1.00 Y 1.50 1.50 20/20 8 to 13
Li et al., 2019146 OK –4.00 to –1.00 (sphere) N? 1.50 NR 20/20 8 to 15
Ruiz-Pomeda et al., 2018145 SCL (concentric bifocal) –4.00 to –0.75 Y 1.00 1.00 20/25 8 to 12
Chamberlain et al., 2019134 SCL (concentric bifocal) –4.00 to –0.75 Y 0.75 1.00 20/25 8 to 12
Sankaridurg et al., 2019135 SCL (multifocal and novel design) –3.50 to –0.75 Y 0.75 NR 20/30 7 to 13
Walline et al., 2020136 SCL (multifocal +1.50 and +2.50 add) –5.00 to –0.75(sphere) Y 1.00 2.00 20/25 7 to 11
Azuara-Blanco et al., 2019147b Atropine (0.01%) –10.00 to –0.50 Y 2.00 NR 20/32 6 to 12
Joachimsen et al., 2019147 Atropine (0.01%) NR NR NR NR NR 6 to 17
McCrann et al., 2019148 Atropine (0.01%) –1.00 or more myopic (least
myopic meridian must be
–0.50 or more myopic)
Y 2.50 NR 20/32 6 to 16
Yam et al., 2019149 Atropine (0.01%, 0.025%, 0.05%) –1.00 or more myopic
refraction
Y 2.50 NR NR 4 to 12
Huang et al., 2019150 SCL (multifocal) plus atropine (0.01%) –5.00 to –0.75 sphere Y 1.00 2.00 20/25 7 to 11
Tan et al., 2019151 OK plus atropine (0.01%) –4.00 to –1.00 Y 2.50 1.00 20/25 6 to 11
Aniso, anisometropia; Ast, astigmatism; N, no; NR, not reported; SCL, soft contact lens; VA, visual acuity; Y, yes; ?, unclear.
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It should be noted that if reporting treatment effects as a
percentage reduction, enrolling older children could yield a
falsely higher increased apparent efficacy, as discussed later.
Enrolling older children also adds additional complexities
such as the necessity of exclusion criteria such as “negative
pregnancy test for females with childbearing potential,”148
as was done in one such trial. In addition to the previ-
ously recommended participant selection criteria,16 several
studies also limited ethnic diversity,132,152 the maximum
amount of myopia (either due to optical correction avail-
ability or increased risk of pathology), birth term/weight,134
and specifically excluded connective tissue disorders such
as Marfan and other more general systemic pathology.135,152
One study required at least 1 parent to be myopic.144 Two
studies required a threshold amount of myopia progression
over the past year as an inclusion criterion,149,150 despite
the previously identified issues with such an entry criterion
including the variability of subjective refraction, determin-
ing progression based on just 2 data points, and the lack
of standardization of the refraction when extracting retro-
spective data from a chart review. None of these differences
in recently published studies would appear to warrant revi-
sion to the previously recommended participant selection
criteria of:
Inclusions.
Refractive error Cyclopleged spherical or





Visual acuity 20/20 minimum
Exclusions.
History Previous rigid lens wear or
myopia control treatment
Ocular disease Any (other than myopia)
Binocular vision Anomaly
Systemic disease Those that may affect vision,
vision development, or the
treatment modality
Medications Those that may affect pupil size,
accommodation, or have an
impact on the ocular surface
If these criteria are not followed, the apparent efficacy
of a treatment may be underestimated and it may be more
difficult to compare approaches across studies.
Study Design
Most of these studies have followed their cohort for 2 years
(Table 4), with an additional year to examine whether there
was any rebound in 2 of the atropine studies and in the
second year in one of the spectacle studies. All studies have
shown a reduced effectiveness of treatments in the second
year, demonstrating why more than 1 year of follow-up is
needed to assess the long-term efficacy of the treatment. The
extrapolation of a 1-year treatment effect to multiple years
(an approach taken by many myopia calculators, for exam-
ple) can lead to incorrect conclusions. Hence, the prior IMI
recommendation of a 3-year minimum length (plus an addi-
tional year of no treatment to examine any rebound effect) of
a clinical trial assessing the efficacy of a treatment for myopia
control is still upheld. All new studies, except one on orthok-
eratology, appropriately applied masking and randomiza-
tion; however, stratification of subjects is rare. Appropriate
controls have been selected for the control group, although
Tan et al.151 did not include a placebo drop in their orthok-
eratology alone control group, which could have identified
those patients in the treatment group who used atropine
drops in addition to orthokeratology.
One ethical dilemma that is now being discussed is the
appropriateness of including a control group in studies. If
the treatment is well enough established to slow or prevent
myopia progression, is it ethical to randomly assign subjects
to an ineffective sham/control group given their likelihood
to develop myopia or have myopic progression? The deci-
sion to include a control group rests on whether treat-
ments with a similar risk profile are well enough estab-
lished to be recommended (as previously indicated by the
IMI clinical trials report)16 or not (as indicated for all ther-
apies except for atropine by a recent Cochrane system-
atic review153 and as is advocated by some professional
bodies).154 Another consideration is whether there should
be triggers within the rebound examination year to rein-
state treatment if myopia progression seems to accelerate
after discontinuing the active treatment. This issue is prob-
lematic as eye growth varies by season throughout the year
and thus is not linear; therefore, determining whether there
has been an acceleration in eye growth is difficult with-
out a full year’s observation. There is also the issue as to
whether good comparative control data on myopia progres-
sion in children already exist in the academic literature that
can serve as a suitable historical control for any cohort of
children recruited to study a new intervention. Progression
differs by age, ethnicity, and season and has been hypoth-
esized to vary depending on environmental factors such as
outdoor time or light levels16; therefore, it is difficult to argue
that a historical control can be expected to adequately repre-
sent, without bias, the progression one would expect with a
randomized control group. Hence, our assessment is that, at
present, an appropriately selected concurrent control group
is still ethical for myopia control trials, along with an addi-
tional full year of no treatment in the treated group, to assess
any rebound effect.
Outcome Measures
The outcomes of myopia progression clinical trials can still
be classified as primary (refractive error and/or axial length),
secondary (patient-reported outcomes and treatment
compliance), and exploratory (peripheral refraction, accom-
modative changes, ocular alignment, pupil size, outdoor
activity/lighting levels, anterior and posterior segment
imaging, and tissue biomechanics).16 However, visual distur-
bances (reported subjectively such as halos and glare or
measured objectively such as with halometry) and patient-
reported outcomes have been further specified in the mini-
mum data set for different modalities of treatment (Table 5).
It has been recently questioned at relevant conferences
whether the slowing of myopia progression should be
reported as a percentage, as has been traditionally done,
or as an absolute/cumulative reduction in myopia progres-
sion (in diopters) or slowed axial elongation (in millime-
ters) between a treatment and control group. This issue has
arisen due to the reduction in treatment efficacy over time
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TABLE 4. Control Group, Randomization, and Masking of Recent Myopia Control Trials









Kanda et al., 2018144 Spectacle (novel plus design) Spectacle (SV) Y N Y 2 N
Lam et al., 2020132 Spectacle (novel plus design) Spectacle (SV) Y N Y 2 N
Li et al., 2019146 OK Spectacle (SV) N N N 1 Y (1 month)
Ruiz-Pomeda et al., 2018145 SCL (concentric bifocal) Spectacle(SV) Y Y N 2 N
Chamberlain et al., 2019134 SCL (concentric bifocal) SCL (SV) Y Y Y 3* Y (planned)†
Sankaridurg et al., 2019135 SCL (multifocal and novel design) SCL (SV) Y N Y 2 N
Walline et al., 2020136 SCL (multifocal +1.50 and +2.50 add) SCL (SV) Y Y Y 3* Y (planned)†
Azuara-Blanco et al.,
2019147b
Atropine (0.01%) Placebo Y N Y 2 N
Joachimsen et al., 2019147 Atropine (0.01%) None N N N 1 N
McCrann et al., 2019148 Atropine (0.01%) Placebo Y Y Y 3 Y (study year 3)
Yam et al., 2019149 Atropine (0.01%, 0.025%, 0.05%) Placebo (year 1 only) Y Y Y 3 Y (study year 3)
Huang et al., 2019150 SCL (multifocal) plus atropine (0.01%) Historical (SCL SV and SCL
multifocal)
N N N 3 N
Tan et al., 2019151 OK plus atropine (0.01%) OK only Y N Y 2 N
SV, single vision.
*Followed for an additional period after ending randomization.
†Based on communication with authors.


































Spectacles X X X X X X X X X X
Soft multifocal contact lenses X X X X X X X X X X X
Orthokeratology X X X X X X X X X X X
Pharmaceuticals X X X X X X X X X X
during a trial, which is presumed to be due to the increasing
age of the children. Another issue with percentages is that
they depend on the rate of progression in the control group;
the same absolute effect size when reported as a percent-
age will appear larger or smaller depending on whether
there is slower or faster myopia progression in the control
group. It has also recently been suggested that perhaps only
a maximum amount of myopia can be prevented by a treat-
ment, regardless of treatment duration. Reporting the over-
all slowing of myopia progression or axial growth between
the treatment and control group seems to be a sensible
suggestion; therefore, we would advocate the reporting of
both a percentage and absolute amount of reduced myopia
progression/axial elongation in future clinical trial reports.
Instrumentation
New instrumentation relevant to myopia progression trials
includes exploratory outcome devices to objectively monitor
working distance155 and light levels to assess key environ-
mental factors. A new aberrometer that utilizes pyramidal
optics (as opposed to Hartmannn–Shack aberrometers) for
measuring ocular aberrations has been developed and vali-
dated on model eyes156 and in humans157 as repeatable and
accurate. Choroidal OCT and angiography have been used to
explore differences in structure and function of this tissue,
particularly in high myopes.158,159
Conclusion
Clinical trials for myopia control must be carefully designed
to inform clinical practice and to better understand the
mechanism of action of treatments to allow further refine-
ments. Some recently published studies still do not include
fundamental elements, such as masking and randomization,
a simultaneous control group, and clearly defined enroll-
ment criteria to minimize bias and the potential to report
inaccurate conclusions. The original 2019 IMI white paper16
and this update can be used by researchers and industry
to inform their clinical trial design. This information can
also be used by clinicians and regulatory bodies to inter-
pret the strength of evidence provided by published trials
and to compare risks and benefits between treatments.
IMI DIGEST 2021—CLINICAL MANAGEMENT
GUIDELINES FOR MYOPIA
The intent of this Yearly Digest is to highlight significant
additions to the clinical management of myopia since the
publication of the of the 2019 IMI white paper on clinical
management guidelines.160 This review takes into account
publications on new interventions and key understandings
of the myopia management landscape, which have influ-
enced how science is translated into practice.
Several notable randomized controlled studies on myopia
control interventions have been published since early 2019.
While examining the detail of these intervention studies
is not the remit of the Yearly Digest, the impact of these
studies on clinician awareness of myopia control options
and how this has influenced clinical management must be
noted. First, 2 new contact lens studies marked a depar-
ture from traditional multifocal contact lens designs, typi-
cally prescribed for presbyopia, to myopia control-specific
designs. The MiSight 3-year134 and extended depth of
focus 2-year135 randomized controlled contact lens studies
presented robust evidence of efficacy to slow both axial and
Downloaded from iovs.arvojournals.org on 10/11/2021
IMI 2021 Yearly Digest IOVS | Special Issue | Vol. 62 | No. 5 | Article 7 | 16
TABLE 6. Summary of Results for Recently Published Myopia Control Intervention Studies
Absolute Difference in Progression Between Treatment and Control Groups
Intervention Study Duration, y Refractive (D) Axial Length (mm)
MiSight contact lens134 3 0.66 0.28
Extended depth of focus contact
lens135 (4 designs tested)
2 0.27 to 0.37 (across 4 test designs) 0.14 to 0.19 (across 4 test designs)
Biofinity +2.50 contact lens136 3 0.45 0.23
DIMS spectacle lens132 2 0.44 0.34
LAMP atropine149
0.01% 1 0.22 0.05
0.025% 0.35 0.12
0.05% 0.54 0.21
Differences between adjusted means are presented as detailed in each paper.
refractive myopia progression. Second, the Defocus Incor-
porated Multiple Segments (DIMS) spectacle lens 2-year
study132 revealed perhaps the strongest efficacy results of
all spectacle lens interventions, arguably similar to that of
contact lens designs. As well, the Bifocal Lenses in Near-
sighted Kids group demonstrated a significant slowing of
axial length and refractive error with the CooperVision-
Biofinity +2.50 D add but not the +1.50 D add lenses
in a 3-year randomized trial136 (discussed in Interventions
for controlling myopia onset and progression). Finally, the
LAMP 1-year study149 provided a control group comparison
that importantly highlighted the concentration-dependent
success of atropine intervention, which had been unclear
from previous studies. The absolute differences in refrac-
tive and axial length outcomes between treatment and
control groups in these studies are provided in Table 6. The
sum total of these studies provides clarity in intervention
evidence and, in combination with increasing availability of
the optical treatments, leads to improved prescribing options
for childhood myopia.
As clinicians have also begun combining atropine with
optical interventions, 2 randomized controlled trials are
currently under way. Recently reported 2-year data on
combining atropine 0.01% with orthokeratology showed no
benefit for children who had more than 3 D and less than 6 D
of myopia at baseline, but 0.11 mm less total axial elongation
in myopes of 1 to 3 D at baseline.161 There was no correla-
tion between age and efficacy of the combined treatment.161
Baseline data for bifocal soft contact lenses combined with
0.01% atropine have also been presented.149
The remit of the Clinical Management Guidelines report
was to canvas all aspects of patient identification, communi-
cation, clinical tests, and guidelines for management. Four
newly published papers describe the current landscape
of myopia control research and practice, as well as key
depictions of the risk-to-benefit balance to assist clinicians
in understanding and communicating the imperative for
myopia management.
Myopia Control 2020: Where are We and Where
are We Heading? Bullimore MA, Richdale K.
Ophthalmic and Physiological Optics
2020;40:254–27018
This review highlighted key outcomes of recent peer-
reviewed literature. Original spectacle lens studies employ-
ing progressive addition and traditional flat-top bifocals
reported no clinically meaningful results, limiting their
uptake by clinicians; however, novel spectacle designs such
as those developed by Hong Kong Polytechnic University
(DIMS) and SightGlassVison are reporting myopia control
results approaching that of contact lens designs. Likewise,
symptoms and rebound associated with 1% atropine were
not considered clinically acceptable, and 0.01% showed little
efficacy in controlling axial elongation. The recent LAMP
study demonstrated excellent tolerability and efficacy with
0.05% atropine and, based on current research, it is arguably
the optimal concentration with which to initiate treatment.
Advances in these modalities provide safe and effective
treatment options for children not ready for or interested
in contact lenses. Children as young as 7 to 8 years of age
can successfully wear contact lenses. The longest myopia
control data available to date, a single orthokeratology
study, demonstrate a myopia control effect of 0.45 mm over
7 years of wear. The 2 recent soft contact lens trials show
excellent 2- and 3-year efficacy in controlling progression
(Table 6). Approval for myopia control varies broadly
by country and may influence practitioner and parental
decisions on treatment.
There is no valid progression-based criterion for initi-
ation of myopia control. Age is the single most impor-
tant factor in predicting progression—with younger chil-
dren typically progressing more quickly—but ethnicity, sex,
and parental history of myopia also influence progression.
The vast majority of children with myopia will progress,
and thus parents should be educated about treatment and
management options as soon as a child develops myopia.
The only caveat to treating all children with myopia is that
some may be considered to have “pathologic” myopia, such
as those developing myopia before the age of 5 years, or in
association with a systemic condition. There is no research
to suggest that standard myopia control treatments will be
effective in these cases. Parents should also be educated to
anticipate that myopia control treatment should be contin-
ued until myopia stabilizes, which is expected to be in the
later teens or early 20s. Future research is aimed at maintain-
ing high safety standards while further improving efficacy of
single and combination treatments.
International Survey of Contact Lens Fitting for
Myopia Control in Children; Efron N, Morgan PB,
Woods CA et al. Contact Lens and Anterior Eye
2020;43:4–8162
Childhood myopia requires correction as well as control;
contact lens interventions show the best propensity for
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achieving both as a monotherapy. Uptake of contact lens
fitting for myopia control (MC) in children was evaluated in
a serial survey. The proportion of pediatric contact lens fits
for MC increased from 0.2% of all fits in 2011 to 6.8% in
2018. This trend is mostly attributable to increase in rigid
lens fitting for MC, particularly since 2016. Rigid lens fits for
myopia control have increased from only a few percent of
all rigid lens fits in 2011 to over 20% from 2016 to 2018,
now representing over half of all MC fits but only 12% of all
non-MC fits.
Variation by country in the proportion of pediatric contact
lens (CL) fits for MC ranged from over 20% of all fits in
Austria, Germany, and Hong Kong to no fits in the Czech
Republic, Japan, South Korea, and Puerto Rico. Across the
31 countries surveyed, children fit for MC are on average
younger (mean 13 years) compared to non-MC fits (mean 15
years); 84% wear their lenses 7 days per week compared to
56% of non-MC fit children.
This survey indicates that despite increases in education
and research, clinical application of contact lenses for child-
hood myopia control is still low. Moreover, the average age
for MC fits in this survey is higher than ideal, given that
intervention at a younger age (before age 12) is indicated to
achieve the greatest myopia control effects.160 The authors
cited international differences in the extent of CL fitting for
MC as due to specific lens availability, along with practi-
tioner training, attitudes, and confidence. Overall low uptake
was described as likely due to lack of on-label products for
most of the survey period and in most parts of the world,
uncertainty about efficacy, and lack of awareness among
parents of MC benefits. As these data were truncated prior
to publication of the IMI Clinical Management Guidelines,
it is hoped that future prescribing surveys will indicate a
continued upward trend in myopia control contact lens fits
to children, along with a downward trend in mean age.
Childhood and Lifetime Risk Comparison of
Myopia Control With Contact Lenses; Gifford KL.
Contact Lens and Anterior Eye 2020;43:26–32163
Barriers to pediatric contact lens prescribing can include
concerns about safety. To address this, the short-term risk of
pediatric contact lens wear for myopia control was compared
to the lifetime risk of myopia-associated pathology. This
analysis determined that the comparative risk of microbial
keratitis (MK) across a lifetime of any type of contact lens
wear, when presumed to commence at age 8 for myopia
control, is less than the lifetime risk of vision impairment
with myopia more than 6 D or axial length more than 26
mm. Childhood contact lens wear risks were calculated over
10 years of wear—from age 8 to 17 inclusive. When added
to these childhood risks, a lifetime of contact lens wear was
modeled by calculation of 47 years of adult contact lens wear
(age 18 to 65 years inclusive) plus 10 years of no contact lens
wear (from 66 to 75 years inclusive). Peer-reviewed data on
infection risk in various contact lens wear modalities were
compared to published cumulative risk of vision impairment
by age 75.
The findings indicated that 10 years of pediatric overnight
orthokeratology wear—the “riskiest” type of myopia control
contact lens wear in childhood—presents a 1 in 66 likelihood
of MK, compared to a 1 in 33 lifetime risk of vision impair-
ment with myopia of 0.5 to 3.0 D. The “riskiest” way to wear
contact lenses over a lifetime was modeled to be 10 years of
childhood reusable soft contact lens wear on a daily sched-
ule with 47 years of adult soft contact lens extended wear,
presenting a 1 in 7.7 lifetime risk of MK. When compared
to lifetime risks presented by myopia to an individual, the
risk of vision impairment is 1 in 3.9 for eyes 26 to 28 mm
long and 1 in 5 for eyes with 6 to 10 D of myopia. Myopia
under 3 D and axial lengths less than 26 mm make a life-
time of orthokeratology or reusable soft contact lens wear
more risky by comparison, while a lifetime of daily dispos-
able wear presents a 1 in 76 risk of MK, which is less than
any of the calculated myopia risks.
These findings provide scientific basis for clinicians to be
proactive in recommending myopia control contact lenses to
younger children, as both the short-term safety profile and
long-term preventative eye health benefits are evident.
Myopia Control: Why Each Diopter Matters;
Bullimore MA, Brennan NA. Optometry and
Vision Science 2019;96:463–465164
While keeping myopia below 6 D and axial length less than
26 mm through myopia control intervention is a key goal,
the value of the smaller goal of 1 D of control is perhaps the
strongest clinical message to emerge since publication of
the IMI Clinical Management Guidelines. Three arguments
for the advantages of 1 D lower myopia are presented. First,
less visual disability while uncorrected and the relationship
to quality of life were explored. As stated by the authors,
“Corrected or not, greater refractive error produces greater
disability and dependence on whatever mode of correction
[is] used.”
Second, improved availability and better visual outcomes
for future surgical myopia correction were described. Laser
in situ keratomileusis has been demonstrated to reduce
best-corrected low-contrast acuity in higher myopes, and
higher ablations can increase risk of postoperative ecta-
sia. Finally, this important analysis demonstrated that across
the range of refractions, each 1 D less of final myopia
translates to 40% less lifetime risk of developing myopic
maculopathy, which is the most common and serious sight-
threatening complication of myopia. This was compared to
the Age-Related Eye Disease Study for age-related macular
degeneration (ARMD), which found a 25% risk reduction in
progression to advanced ARMD through years of adminis-
tration of antioxidants plus zinc. When viewed similarly as
a preventative eye health treatment, and that most myopia
control interventions pose low relative risk, reducing an indi-
vidual’s final level of myopia by 1 D presents a clear public
health imperative for reducing future visual impairment for
millions of myopes around the world. The authors note that
while research continues on treatment options and their
absolute efficacy, and long-term data are lacking, it is reason-
able to speculate that currently available myopia control
interventions could provide a cumulative treatment effect
of 1 D. This simple perspective on what is a complex field
provides the clinical “why” for proactive myopia manage-
ment.
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